Revelation Biosciences (NASDAQ: REVB) has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).
Avance Clinical will manage site identification and management, patient recruitment, safety monitoring, and data management including completeness, accuracy and analysis.
In a statement, James Rolke, CEO of Revelation, commented, “The company selected Avance Clinical following an extensive evaluation process. Working closely with Avance, the Revelation team remains committed to starting this important study later this year.”
